Abstract
Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.
| Original language | English |
|---|---|
| Pages (from-to) | 19-28 |
| Number of pages | 10 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 19 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2 2019 |
Fingerprint
Keywords
- biomarkers
- cfDNA
- Liquid biopsy
- next generation sequencing
- non-small-cell lung cancer
- tumor genotyping
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)
Cite this
The role of circulating free DNA in the management of NSCLC. / Esposito Abate, Riziero; Pasquale, Raffaella; Fenizia, Francesca; Rachiglio, Anna Maria; Roma, Cristin; Bergantino, Francesca; Forgione, Laura; Lambiase, Matilde; Sacco, Alessandra; Piccirillo, Maria Carmela; Morabito, Alessandro; Normanno, Nicola.
In: Expert Review of Anticancer Therapy, Vol. 19, No. 1, 02.01.2019, p. 19-28.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - The role of circulating free DNA in the management of NSCLC
AU - Esposito Abate, Riziero
AU - Pasquale, Raffaella
AU - Fenizia, Francesca
AU - Rachiglio, Anna Maria
AU - Roma, Cristin
AU - Bergantino, Francesca
AU - Forgione, Laura
AU - Lambiase, Matilde
AU - Sacco, Alessandra
AU - Piccirillo, Maria Carmela
AU - Morabito, Alessandro
AU - Normanno, Nicola
PY - 2019/1/2
Y1 - 2019/1/2
N2 - Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.
AB - Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.
KW - biomarkers
KW - cfDNA
KW - Liquid biopsy
KW - next generation sequencing
KW - non-small-cell lung cancer
KW - tumor genotyping
UR - http://www.scopus.com/inward/record.url?scp=85058737930&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058737930&partnerID=8YFLogxK
U2 - 10.1080/14737140.2019.1548938
DO - 10.1080/14737140.2019.1548938
M3 - Review article
C2 - 30462523
AN - SCOPUS:85058737930
VL - 19
SP - 19
EP - 28
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 1
ER -